Danofloxacin-d3 Mesylate is a fluoroquinolone antibiotic which inhibits gram-negative bacteria. It is believed that Danofloxacin-d3 Mesylate inhibits Topo II (DNA gyrase) and triggers the activation of the SOS pathway along with temperate bacteriophages to inhibit bacterial growth. In addition, studies indicate that Danofloxacin-d3 Mesylate is a substrate for efflux-transporters such as P-gp, BCRP and MRP2, which are members of the ATP-Binding Cassette (ABC) superfamily. Ko 143 (sc-204030) can inhibit the secretion of Danofloxacin-d3 Mesylate from BCRP but does not affect its absorption. Furthermore, MK-571 (sc-201340), an inhibitor of MRPs, can increase the absorption of Danofloxacin-d3 Mesylate on the apical membrane of Caco-2 cells. Also studies suggest that Danofloxacin-d3 Mesylate shows a stronger inhibiting effect in lysogenic E. coli bearing lambda prophages than in nonlysogenic E. coli.
1. Froshauer, S., et al. 1996. Antimicrob. Agents Chemother. 40: 1561-1563. PMID: 8726041
2. Schrickx, J.A. and Fink-Gremmels, J. 2007. Br. J. Pharmacol. 150: 463-469. PMID: 17211460
Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.